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The low-prevalence MNS blood group antigenTSEN is located at the
junction of glycophorin A (GPA) to glycophorin B (GPB) in several
hybrid glycophorin molecules. Extremely rare people have RBCs
with a double dose of theTSEN antigen and have made an antibody
to a high-prevalence MNS antigen. We report the first patient who
is heterozygous for GYP.JL andMk. During prenatal tests,an alloanti-
body to a high-prevalence antigen was detected in the serum of a
21-year-old Hispanic woman. The antibody detected an antigen
resistant to treatment by papain, trypsin, α-chymotrypsin, or DTT.
The antibody was strongly reactive by the IAT with all RBCs tested
except those having the MkMk, GP.Hil/GP.Hil, or GP.JL/GP.JL
phenotypes. The patient’s RBCs typed M+N–S+/–s–U+, En(a+/–),
Hut–, Mi(a–), Mur–, Vw–, Wr(a–b–), and were TSEN+, MINY+.
Reactivity with Glycine soja suggested that her RBCs had a
decreased level of sialic acid. Immunoblotting showed the presence
of monomer and dimer forms of a GP(A-B) hybrid and an absence of
GPA and GPB. Sequencing of DNA and PCR-RFLP using the
restriction enzyme RsaI confirmed the presence of a hybrid GYP(A-
B). The patient’s antibody was determined to be anti-EnaFR. She is
the first person reported with the GP.JL phenotype associated
with a deletion of GYPA and GYPB in trans to GYP.JL.
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The antigens of the MNS blood group system are
carried on glycophorin A (GPA), glycophorin B (GPB),
or various hybrid molecules thereof. The antigens arise
from single amino acid substitutions in GPA or GPB, the
novel amino acid sequences formed at the junction
of GPA to GPB or the junction of GPB to GPA, or
expression of amino acids encoded by the pseudo exon
of the GYPB gene.1
The low-prevalence MNS RBC antigens,TSEN and
MINY,are located at the junction of GPA (3′ end of GYPA
exon 3) to GPB (5′ end of GYPB exon 4) in the GP(A-B)
hybrid associated with GP.JL (Mi.XI), and in the GP(B-A-
B) hybrid associated with GP.Hop (Mi.IV).2,3 These
rearranged genes can be detected by altered RsaI
restriction enzyme sites.4 However, these hybrid genes
are not distinguished by this restriction enzyme from
the hybrid genes that encode hybrid glycophorin
molecules that carry Hil, namely GP.Hil (Mi.V), GP.Mur
(Mi.III),GP.Bun (Mi.VI), and GP.HF (MI.X).1,4
TSEN+ RBCs are usually found because of a
discrepant S typing or by detection of an antibody to a
low-prevalence antigen.2,5,6 Extremely rare people have
RBCs with a double dose of TSEN and have made an
antibody to a high-prevalence MNS antigen.7,8 We report
a person who is heterozygous for GYP.JL and Mk (the
null allele in the MNS system).
Case Report
We report a case of a 21-year-old group O Hispanic
woman in her second pregnancy. During prenatal tests,
an alloantibody to a high-prevalence antigen lacking
from her RBCs was detected in her serum. The proband
had no history of transfusion. Her first pregnancy ended
in miscarriage for reasons unrelated to the antibody;her
second pregnancy resulted in the birth of an apparently
healthy baby girl whose RBCs typed as group A, D+.
RBCs from the baby’s cord blood sample were positive
in the DAT (3+) with anti-IgG. An eluate prepared from
these RBCs was reactive with all RBCs except those of
the mother. The baby’s serum also contained the
antibody, albeit weakly reactive. The mother and baby
were discharged the day after the baby was born, and
there is no indication in the records that the baby
required special care.
Material and Methods
Serologic testing of patient RBCs and serum was
performed by standard tube hemagglutination.
Treatment of intact RBCs with papain, trypsin, α-
chymotrypsin, or 200 mM DTT; DNA extraction from
WBCs;DNA sequencing;and PCR-RFLP were performed
I M M U N O H E M A T O L O G Y, VO L U M E 2 3 , N U M B E R 4 , 2 0 0 7 147
Alloantibody in a GP.JL/Mk person
by standard methods.9,10 Immunoblotting of mem-
branes prepared from RBCs was also performed by
standard method under nonreducing conditions using
a commercial monoclonal anti-GPA/B (E3, Sigma
Biologicals, St. Louis, MO) as the primary antibody and
a peroxidase-conjugated rabbit anti-mouse IgG as the
secondary antibody (MP Biomedicals,Aurora,OH).
Results
Hemagglutination
The alloantibody in the proband’s serum reacted
strongly (4+) by the IAT with all RBCs tested, including
Wr(a+b–) RBCs,but did not react with RBCs having the
MkMk (MNS null phenotype),GP.Hil/GP.Hil (Mi.V/Mi.V),
or GP.JL/GP.JL (Mi.XI/Mi.XI) phenotypes, all of which
areWr(a–b–). The antigen detected by the antibody was
resistant to treatment of RBCs with papain, trypsin, α-
chymotrypsin,or DTT. These results are consistent with
the presence of anti-EnaFR in the patient’s serum. The
antibody had a titer of 128 by saline-IAT. RBCs from the
proband’s mother, brother, and sister typed TSEN– and
were strongly agglutinated (4+) by the patient’s serum.
Other family members were not available for testing.
The proband’s RBCs typed M+N–S+/– (positive with
four polyclonal and one monoclonal [MS95] anti-S, and
negative with one polyclonal and one monoclonal
[MS94] anti-S),s–U+,En(a+/–) (weakly positive with five
and negative with four polyclonal anti-Ena), He–, Hut–,
Mi(a–), Mt(a–), Mur–, Vw–,Wr(a–b–) (with two poly-
clonal and five monoclonal anti-Wrb), and were TSEN+,
and MINY+, suggesting a GP.JL phenotype. The
proband’s RBCs were pedestrian with regard to other
blood group antigens.
The proband’s RBCs were strongly agglutinated by
Glycine soja lectin, suggesting they had a decreased
level of sialic acid. The results of testing the proband’s
RBCs with monoclonal anti-GPA directed at different
epitopes on GPA (anti-GPAMSer1, anti-GPAMGly5, anti-
GPA1-26,anti-GPA38-44, anti-GPA34-48, and anti-GPA49-
55) suggested that the proband’s RBCs express the N-
terminal portion of GPA.
Immunoblotting
Immunoblotting of RBC membranes made from the
proband’s sample with monoclonal anti-GPA+GPB (E3,
Sigma) showed the presence of monomer and dimer
forms of a hybrid GP (A-B) and the absence of GPA and
GPB (Fig. 1).
DNA analyses
Sequencing of genomic DNA isolated from the
proband’sWBCs confirmed the presence of a GYP(A-B)
hybrid in which exon 3 is from GYPA and exon 4 is from
GYPB (Fig. 2). This change ablates an RsaI restriction
enzyme site at nucleotide 242 (T>G) and introduces an
RsaI site at nucleotide 266 (A>T). PCR-RFLP analysis
after RsaI digestion gave bands of 206 bp and 143 bp
for the proband’s hybrid glycophorin gene, compared
with bands of 182 bp and 167 bp for GYPA (Fig. 3).
Analysis of DNA isolated from WBCs from the
proband’s mother, brother, and sister showed that the
hybrid GYPA-GYPB gene was not present.
Discussion
We describe the first person with a probable
GP.JL/Mk genotype who has made an alloanti-EnaFR.
Anti-Ena is a broad term representative of a group of
antibodies that react with different epitopes on GPA,
the glycoprotein carrying MN. Anti-Ena may be an
Fig. 1. Immunoblot of RBC membranes using Mab anti-GPA+GPB. As is
typical with Mab anti-GPA+GPB (E3,Sigma), stronger staining was
obtained with GPB than with GPA. “GP.JL Hetero”is from a control,
known heterozygous GYP.JL, unrelated person. The RBCs from
the “Normal” in lane 2 typed M+N–S+s+ and in lane 4 typed
M+N+S+s+. The arrows indicate the GP.JL glycoprotein:monomer
(lowest band) and homodimer (upper band) in both “Proband”
and“GP.JL Hetero”samples,and the heterodimer,GPB/GP.JL, in the
“GP.JL Hetero”sample.
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autoantibody or, as in this case, an alloantibody
recognizing a portion of GPA that is altered on or
lacking from the RBCs of the individual who made the
antibody. The antibody present in the proband’s serum
is directed at a ficin- (and papain-) resistant epitope on
normal GPA close to the RBC membrane, which is
lacking on her RBCs. This is in contrast to anti-EnaFS and
anti-EnaTS,which are antibodies directed at,respectively,
ficin-sensitive and trypsin-sensitive antigenic determi-
nants at the N-terminal of this region on GPA.
The proband’s RBCs areTSEN+,MINY+ and appear
to have a double dose of these antigens as a result of the
presumed (based on the Glycine soja and immuno-
blotting results) presence ofMk in trans to GYP.JL. The
S antigen on the proband’s RBCs is altered, as would be
expected, because her RBCs are TSEN+. The Wr(b–)
status of her RBCs is also expected because, although
Wrb is associated with a point mutation on band 3,Wrb
expression requires the presence of amino acid residues
59 to 76 of GPA that are lacking from RBCs with a
double dose of GP.JL and GP.Hil.11,12 This explains why
previously reported cases of individuals homozygous for
genes encoding GP.JL (Mi.XI) were described as having
anti-Wrb, anti-Wrb/EnaFR, or mixtures thereof in their
serum.7,8,13 Indeed, anti-Wrb is an anti-EnaFR. However,
not all anti-EnaFR are anti-Wrb,and there is heterogeneity
in these antibodies.
The altered RsaI sites provide a means to perform
PCR-RFLP analysis to detect the genes encoding TSEN
and Hil.
The baby appeared to be unaffected by the mother’s
antibody, and it is tempting to speculate that the
difference inABO type (mother group O,baby groupA)
may have had a protective effect.
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Fig. 2. Alignment of gDNA nucleotide sequences using GYPA-specific primers for the flanking regions of exon 4 of the proband, compared with normal
GYPA and GYPB. Uppercase letters indicate nucleotides in exon 4, and lowercase letters indicate nucleotides in intron 3 (upper line) and intron 4
(lower line). Dashes (–) represent consensus nucleotides using GYPA as the reference sequence. In the Proband, exon 4 is GYPB-specific.
Fig. 3. PCR-RFLP of GYPA exon 4 using RsaI. An 8% polyacrylamide gel
demonstrating a band pattern of 182 bp and 167 bp for the
“normal” GYPA control sample and for four relatives of the
proband. The“Proband”sample gave bands of 206 bp and 143 bp.
A sample containing equal parts of the proband’s DNA and
“normal”DNA gave bands of 206 bp, 182 bp, 167 bp, and 143 bp.
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